Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort.

Autor: Erickson CM; Department of Medical Ethics and Health Policy University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA., Chin NA; Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA., Rosario HL; Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA., Peterson A; Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA., Johnson SC; Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.; Wisconsin Alzheimer's Institute University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.; Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA., Clark LR; Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.; Geriatric Research Education and Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA.
Jazyk: angličtina
Zdroj: Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2023 Jul 29; Vol. 9 (3), pp. e12413. Date of Electronic Publication: 2023 Jul 29 (Print Publication: 2023).
DOI: 10.1002/trc2.12413
Abstrakt: Introduction: Increased availability of Alzheimer's disease (AD) biomarker tests provides older adults with opportunities to seek out and learn results. We evaluated the feasibility of virtually returning AD biomarker results.
Methods: Trained study clinicians disclosed amyloid positron emission tomography (PET) results and provided dementia risk-reduction counseling via televideo to cognitively unimpaired participants already enrolled in AD research ( n = 99; mean age ± SD: 72.0 ± 4.8; 67% women; 95% White; 28% amyloid elevated).
Results: Our study demonstrated acceptable levels of retention (93%), compliance (98%), adherence (98%), clinician competence (97%), education comprehension (quiz scores 14/15), and virtual visit functionality (rating 9.4/10). Depression, anxiety, and suicidality remained low and did not differ by amyloid result.
Discussion: Virtual return of amyloid PET results to cognitively unimpaired research participants is feasible and does not result in increased psychological symptoms. Technological barriers for some participants highlight the need for flexibility. These findings support the use of televideo in AD biomarker disclosure, although our study sample and design have important limitations for generalizability.
Competing Interests: S.C.J. has in the past 2 years served on advisory boards to Roche Diagnostics, Prothena, AlzPath, Merck, and Eisai. His institution has received research funding from Cerveau Technologies. The rest of the authors have no relevant conflicts of interest to disclose. Author disclosures are available in the Supporting Information.
(© 2023 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
Databáze: MEDLINE
Externí odkaz: